The Pharmacy Times® Cardiovascular Health Resource Center is a comprehensive resource for clinical news and expert insights on the health of the heart and blood vessels, including coronary heart disease, stroke, heart failure, heart arrhythmias, and heart valve issues.
September 12th 2025
Pharmacists enhance patient safety by addressing common medication errors, ensuring proper drug use, and improving therapeutic outcomes in clinical practice.
Neighborhood Marginalization Worsens Outcomes in Young Myocardial Infarction Survivors
August 27th 2025Young adults who had experienced an acute myocardial infarction and lived in marginalized communities had increased risks of adverse events and reduced visits to their physician or cardiologist.
Read More
Tirzepatide Provides Robust Cardiovascular Protection Versus Dulaglutide in T2D, ASCVD
August 4th 2025In the SURPASS-CVOT clinical trial, tirzepatide was non-inferior to dulaglutide in a composite score of cardiovascular outcomes in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD).
Read More
Meta-Analysis Suggests P2Y12 Inhibitor Is a Better Choice for Long-Term Single Antiplatelet Therapy
July 29th 2025A meta-analysis suggests that long-term P2Y12 inhibitor monotherapy after percutaneous coronary intervention may offer superior protection against major adverse cardiac and cerebrovascular events compared with aspirin, without increasing major bleeding risk—potentially challenging current guideline recommendations for antiplatelet therapy beyond 1 year.
Read More
ISTH 2025: Abelacimab Demonstrates Low Periprocedural Bleeding Rates in Phase 2 Trial
Jeffrey I. Weitz, OC, MD, FAHA, FRCPC, FACP, FRSC, FACC, FESC, FCAHS, discusses AZALEA-TIMI 71 trial data showing that the long-acting factor XI inhibitor abelacimab is associated with low periprocedural bleeding risk, supporting potential simplification of anticoagulation protocols for most elective and some urgent procedures.
Read More
Hypertension: A Silent Killer Requiring Novel Therapies
Hypertension is widespread and linked to serious health risks, but new treatments for resistant cases target new mechanisms of action.
Read More
Finerenone Approved by FDA for Treatment of Adults With Heart Failure
July 14th 2025Previously indicated to reduce the risk of end-stage kidney disease, cardiovascular death, and hospitalization for heart failure (HF) in chronic kidney disease, finerenone is now approved for patients with HF directly, offering a new treatment option.
Read More
Highlights From NLA 2025: Early LDL-C Reduction and Emerging Therapies
July 9th 2025The 2025 National Lipid Association (NLA) Scientific Sessions highlighted a strategic shift toward early, aggressive cardiometabolic intervention, underscoring the vital role of pharmacists in implementing emerging therapies and optimizing cardiovascular risk reduction.
Read More